文献速递糖尿病

速效门冬胰岛素在1型糖尿病基础-餐时治疗中改善血糖控制:一项26周多中心、活性对照、达标治疗、随机平行组试验(onset 1)

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
PubMed 文献 · Diabetes Care · 2017-03-29

这项多中心、达标治疗、3期试验比较速效门冬胰岛素(faster aspart)与常规门冬胰岛素(IAsp)在成人1型糖尿病中的疗效与安全性。主要终点为26周HbA1c自基线的变化。结果显示,餐时速效门冬胰岛素相比IAsp统计学显著降低HbA1c,且餐后血糖增量更低;两种治疗的低血糖总体发生率和安全性相似。

要点

  • 餐时速效门冬胰岛素相比IAsp统计学显著降低HbA1c(估计治疗差异-0.15%[95%CI -0.23;-0.07],P=0.0003)。
  • 餐时速效门冬胰岛素在餐后1小时和2小时血糖增量均统计学显著低于IAsp。
  • 速效门冬胰岛素与IAsp的严重或血糖确证性低血糖总体发生率及安全性相似。

核心结论

  • 速效门冬胰岛素有效改善HbA1c,并确认对IAsp的非劣效性,餐时速效门冬胰岛素相比IAsp餐后血糖控制更优。
  • 随机分配至所有餐次餐后注射速效门冬胰岛素的受试者,其HbA1c维持非劣效于餐时注射IAsp。

研究设计与样本

  • 多中心、达标治疗、3期试验,纳入成人1型糖尿病患者。
  • 经过8周导入期后,受试者按1:1:1随机分配至双盲餐时速效门冬胰岛素(n=381)、双盲餐时IAsp(n=380)或开放标签餐后速效门冬胰岛素(n=382),每组均联合地特胰岛素。
  • 主要终点为26周后HbA1c自基线的变化。

主要发现

  • 两个治疗组HbA1c均降低,餐时速效门冬胰岛素与IAsp的估计治疗差异为-0.15%(95%CI -0.23;-0.07),餐后速效门冬胰岛素与IAsp的估计治疗差异为0.04%(95%CI -0.04;0.12),两者对IAsp的非劣效性均得到确认。
  • 餐时速效门冬胰岛素相比IAsp统计学显著降低HbA1c(P=0.0003)。
  • 餐后1小时血糖增量:餐时速效门冬胰岛素相比IAsp的估计治疗差异为-1.18 mmol/L(95%CI -1.65;-0.71),-21.21 mg/dL(95%CI -29.65;-12.77),P<0.0001。
  • 餐后2小时血糖增量:餐时速效门冬胰岛素相比IAsp的估计治疗差异为-0.67 mmol/L(95%CI -1.29;-0.04),-12.01 mg/dL(95%CI -23.33;-0.70),P=0.0375;餐时速效门冬胰岛素对IAsp在2小时血糖增量方面的优效性得到确认。
  • 严重或血糖确证性(血浆葡萄糖<3.1 mmol/L[56 mg/dL])低血糖事件的总体发生率和安全性特征在各治疗间相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multicenter, treat-to-target, phase 3 trial evaluated the efficacy and safety of fast-acting insulin aspart (faster aspart) versus conventional insulin aspart (IAsp) in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: The primary end point was change from baseline in HbA1c after 26 weeks. After an 8-week run-in, subjects were randomized (1:1:1) to double-blind mealtime faster aspart (n = 381), IAsp (n = 380), or open-label postmeal faster aspart (n = 382)-each with insulin detemir. RESULTS: HbA1c was reduced in both treatment groups, and noninferiority to IAsp was confirmed for both mealtime and postmeal faster aspart (estimated treatment difference [ETD] faster aspart-IAsp, mealtime, -0.15% [95% CI -0.23; -0.07], and postmeal, 0.04% [-0.04; 0.12]); mealtime faster aspart statistically significantly reduced HbA1c versus IAsp (P = 0.0003). Postprandial plasma glucose (PPG) increments were statistically significantly lower with mealtime faster aspart at 1 h (ETD -1.18 mmol/L [95% CI -1.65; -0.71], -21.21 mg/dL [-29.65; -12.77]; P < 0.0001) and 2 h (-0.67 mmol/L [-1.29; -0.04], -12.01 mg/dL [-23.33; -0.70]; P = 0.0375) after the meal test; superiority to IAsp for the 2-h PPG increment was confirmed. The overall rate of severe or blood glucose-confirmed (plasma glucose <3.1 mmol/L [56 mg/dL]) hypoglycemic episodes and safety profiles were similar between treatments. CONCLUSIONS: Faster aspart effectively improved HbA1c, and noninferiority to IAsp was confirmed, with superior PPG control for mealtime faster aspart versus IAsp. Subjects randomized to postmeal faster aspart for all meals maintained HbA1c noninferior to that obtained with mealtime IAsp.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Russell-Jones D, Bode BW, De Block C, et al. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diabetes Care. 2017. PMID: 28356319. doi:10.2337/dc16-1771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。